Pain Clinical Trial
— HortONSOfficial title:
Treatment of Chronic Cluster Headache (Horton's Headache) With Transcutaneous Electrical Nerve Stimulation and Occipital Nerve Stimulation
Verified date | May 2024 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is an investigator-initiated, prospective, randomized, placebo-controlled, double blind clinical trial that aims to investigate the effect of transcutaneous electrical nerve stimulation (TENS) and occipital nerve stimulation (ONS) on attack frequency and severity in patients with chronic cluster headache (CH). Study outline Month 1: Baseline. Establishment of a baseline profile of the participants CH attacks (severity, duration, medicine utilization etc), health-related quality of life (QoL) and symptoms of anxiety and depression. No active treatment. Follow-up visit after 30 days. Months 2-4: TENS period. All participants will receive TENS-treatment. Clinical follow-up visit by the end of month four. Months 5-7: Double-blinded, randomized experimental period. All participants will have an ONS-system (lead, impulse generator) implanted and will be randomized 1:1 to receive either 1) burst (paresthesia-free) ONS or 2) placebo (deactivated ONS system). Clinical follow-up visit by the end of month seven. Months 8-10: Open label period. All participants will receive tonic (conventional, paresthesia-inducing) ONS. Clinical follow-up visit by the end of month ten. During every study phase each participant will fill out a weekly electronic headache registration as well as answering questionnaires regarding health-related quality of life and symptoms of anxiety and depression before every follow-up visit.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | July 31, 2024 |
Est. primary completion date | July 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age 18 years and above 2. Signed informed written consent 3. Diagnosed with chronic CH according to the ICHD-3 criteria 4. 15 or more CH attacks per month 5. Stable use of preventive headache medication one month prior to enrollment Exclusion Criteria: 1. Other ongoing neuromodulation therapy 2. Current alcohol and/or drug abuse 3. Severe psychiatric disorder 4. Other chronic primary or chronic secondary headache disorder (e.g. chronic migraine) 5. Major posterior neck surgery in C2-C3 level and above 6. Pregnancy 7. Treatment with oral steroids or GON injection within one month of study participation |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus N |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus | Aarhus University Hospital, Danish Headache Center |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 30% reduction in CH attack frequency with TENS- and ONS-treatment | Proportion of participants with a positive treatment outcome of a 30% reduction in CH attack frequency compared to baseline.
A CH attack is here defined as any attack recognised by the patient as a CH attack. |
Primary evaluation through month 4 (TENS) and 7 (ONS, blinded) | |
Primary | Incidence of treatment-emerged adverse events [safety] in TENS treatment | Treatment related adverse events and adverse device effects will be registered on an ongoing basis. Serious events will be handled immediately. | Evaluation at month 4 | |
Primary | Incidence of treatment-emerged adverse events [safety] in ONS treatment | Treatment related adverse events and adverse device effects will be registered on an ongoing basis. Serious events will be handled immediately. | Evaluation at month 7 (burst ONS) and 10 (tonic ONS) | |
Secondary | 30% reduction of pain intensity in CH attacks | Weekly self reported pain intensity on a numeric rating scale from 0-10 with 0 being "no pain" and 10 "the worst possible pain".
Proportion of participants with a positive treatment outcome of a 30% reduction in pain intensity during CH attacks compared to baseline. |
Through month 4, 7 and 10 | |
Secondary | Feasibility of TENS as a predictor for the efficacy of ONS treatment | Comparison will be made of headache data from the last month of treatment with TENS and tonic ONS, respectively, to evaluate whether a 30% reduction in CH attack duration with TENS-treatment correlates to a 30% reduction in CH attack duration with ONS-treatment. | Through month 4 and 10 | |
Secondary | Non-inferiority study: Burst ONS versus tonic ONS | Comparing treatment outcome of burst ONS and tonic ONS. | Through month 7 and 10 | |
Secondary | Patient-perceived Global Impression of Change (PGIC) | The number of participants who rates their condition 'much improved' or 'very much improved' as assessed by PGIC. | At month 4, 7 and 10 | |
Secondary | Reduction in background headache | Proportion of participants reporting a reduction in background headache. A positive treatment outcome will be defined as a two-point improvement on a four-point scale compared to baseline. | At month 4, 7 and 10 | |
Secondary | Hospital anxiety and depression scale (HADS) | HADS is a self-assessment questionnaire consisting of seven items each for depression and anxiety sub-scales. Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level.
HADS score will be evaluated at every follow up and compared to baseline. |
At month 4, 7 and 10 | |
Secondary | Health-related quality of life (EuroQoL 5D-5L) | The EQ 5D-5L is a well-established measure of health-related quality of life that is quantified as a utility (a measure of quality of life between 0 and 1) based on a danish value set. Furthermore a total score that ranges from 0-100 (visual analog scale), a higher score indicates better health-related quality of life. | At month 4, 7 and 10 | |
Secondary | Self reported sleep quality | Proportion af participants reporting a positive treatment outcome defined as a two-point improvement on a four-point scale compared to baseline. | At month 4, 7 and 10 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|